Jump to Main Content


FDA Warns About the Risks Associated with the Investigational use of Venclexta in Multiple Myeloma

The Food and Drug Administration is alerting health care professionals, oncology clinical investigators and patients about the risks associated with the investigational use of Venclexta (venetoclax) for the treatment of patients with multiple myeloma based on data from a clinical trial. Venclexta is not approved for the treatment of multiple myeloma.